Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial-Reference-Cited by-同舟云学术

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

Published:2010-01 Issue:3 Volume:28 Page:840-848
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Keitel Wendy,Groth Nicola,Lattanzi Maria,Praus Michaela,Hilbert Anne Katrin,Borkowski Astrid,Tsai Ted F.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference31 articles.

1. Keitel WA, Atmar RL. Vaccines for pandemic influenza: summary of recent clinical trials. In: Compans RW, editor. Vaccines for pandemic influenza. Curr Top Microbiol Immunol. 2009;333:431–51.

2. Report of the 5th meeting of the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12–13 February 2009;Hayden;Vaccine,2009

3. Current status and progress of prepandemic and pandemic influenza vaccine development;Leroux-Roels;Expert Rev Vaccines,2009

4. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine;Treanor;New Engl J Med,2006

5. MF59®-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults;Banzhoff;PLoS ONE,2009

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality attributes of CTVad1, a nanoemulsified adjuvant for phase I clinical trial of SpiN COVID-19 vaccine;Nanomedicine;2023-08

2. Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults;Human Vaccines & Immunotherapeutics;2023-01-02

3. MnO₂nanoparticles as a minimalist multimode vaccine adjuvant/delivery system to regulate antigen presenting cells for tumor immunotherapy;Journal of Materials Chemistry B;2022

4. Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults;Vaccines;2021-12-11

5. Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture–derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects;Vaccine;2021-11